As PD1 checkpoint blockade plus chemotherapy has been approved as the first-line treatment for gastro-esophageal cancer patients in many countries [4, 8], we also evaluated HSPA4 expression in responders and non-responders of GC patients receiving PD1 checkpoint blockade combined with chemotherapy. This evidence concerns the gene HSPA4 and gastric cancer.